[1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer 3 statistics, 2012.CA Cancer J Clin 2015;65:87-108.10.3322/caac.21262]Search in Google Scholar
[2. Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med 2015;21:1350-1356.10.1038/nm.3967]Search in Google Scholar
[3. Jiang Q, Ma L, Li R, Sun J. Colon cancer-induced interleukin-35 inhibits beta-catenin-mediated pro-oncogenic activity. Oncotarget 2017;9:11989-1199810.18632/oncotarget.22857]Search in Google Scholar
[4. Zou S, Fang L, Lee MH. Dysbiosis of gut microbiota in promoting the development of colorectal cancer. Gastroenterol Rep (Oxf) 2018;6:1-12.10.1093/gastro/gox031]Search in Google Scholar
[5. Zou S, Fang L, Lee MH. Epithelial Smad4 Deletion Up-Regulates Inflammation and Promotes Inflammation-Associated Cancer. Cell Mol Gastroenterol Hepatol 2018;6:257-276.10.1016/j.jcmgh.2018.05.006]Search in Google Scholar
[6. Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. Immunity 2013;39:1003-1018.10.1016/j.immuni.2013.11.010]Search in Google Scholar
[7. Günther S, Deredge D, Bowers AL, Luchini A, Bonsor DA, Beadenkopf R, Liotta L, Wintrode PL, Sundberg EJ. IL-1 Family Cytokines Use Distinct Molecular Mechanisms to Signal through Their Shared Co-receptor. Immunity 2017;47:510-523.10.1016/j.immuni.2017.08.004]Search in Google Scholar
[8. Wasmer M-H, Krebs P. The Role of IL-33-Dependent Inflammation in the Tumor Microenvironment. Frontiers in Immunology 2016;7:682.10.3389/fimmu.2016.00682]Search in Google Scholar
[9. Ali S, Mohs A, Thomas M, Klare J, Ross R, Schmitz ML, Martin MU. The dual function cytokine IL-33 interacts with the transcription factor NF-κB to dampen NF-κB-stimulated gene transcription. J Immunol 2011;187:1609-1616.10.4049/jimmunol.1003080]Search in Google Scholar
[10. Yao Z, Fanslow WC, Seldin MF, Rousseau AM, Painter SL, Comeau MR, Cohen JI, Spriggs MK. Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity 1995;3:811-821.10.1016/1074-7613(95)90070-5]Search in Google Scholar
[11. Hymowitz SG, Filvaroff EH, Yin JP, Lee J, Cai L, Risser P, Maruoka M, Mao W, Foster J, Kelley RF, Pan G, Gurney AL, de Vos AM, Starovasnik MA. IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding. EMBO J. 2001;20:5332-5341.10.1093/emboj/20.19.533212564611574464]Search in Google Scholar
[12. Moseley TA, Haudenschild DR, Rose L, Reddi AH. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev 2003;14:155-174.10.1016/S1359-6101(03)00002-9]Search in Google Scholar
[13. Gaffen SL. Biology of recently discovered cytokines: interleukin-17--a unique inflammatory cytokine with roles in bone biology and arthritis. Arthritis Res Ther 2004;6:240-247.10.1186/ar1444]Search in Google Scholar
[14. Michel ML, Mendes-da-Cruz D, Keller AC, Lochner M, Schneider E, Dy M, Eberl G, Leite-de-Moraes MC. Critical role of ROR-γt in a new thymic pathway leading to IL-17-producing invariant NKT cell differentiation. Proc Natl Acad Sci U S A 2008;105:19845-51980.10.1073/pnas.0806472105]Search in Google Scholar
[15. Ciric B, El-behi M, Cabrera R, Zhang GX, Rostami A. IL-23 drives pathogenic IL-17-producing CD8+ T cells. J Immunol 2009;182:5296-5305.10.4049/jimmunol.0900036]Search in Google Scholar
[16. O’Brien RL, Roark CL, Born WK. IL-17-producing gammadelta T cells. Eur J Immunol 2009;39:662-666.10.1002/eji.200839120]Search in Google Scholar
[17. Jovanovic M, Gajovic N, Zdravkovic N, Jovanovic M, Jurisevic M, Vojvodic D, Maric V, Arsenijevic A, Jovanovic I. Fecal Galectin-3: A New Promising Biomarker for Severity and Progression of Colorectal Carcinoma. Mediators Inflamm 2018;2018:8031328.10.1155/2018/8031328]Search in Google Scholar
[18. Jovanovic M, Gajovic N, Zdravkovic N, Jovanovic M, Jurisevic M, Vojvodic D, Mirkovic D, Milev B, Maric V, Arsenijevic N. Fecal galectin-1 as a potential marker for colorectal cancer and disease severity. Vojnosanit Pregl (2018); DOI: https://doi.org/10.2298/VSP171201007J.10.2298/VSP171201007J]Search in Google Scholar
[19. Hamilton SR and Aaltonen LA. Pathology and genetics:tumours of the digestive system, in World Health Organization Classification of Tumours, IARC, Lyon, France, 3rd edition, 2000. 103-143.]Search in Google Scholar
[20. Lanza G, Messerini L, Gafa R, Risio M. Colorectal tumors: the histology report. Dig Liver Dis 2011;43 Suppl 4:S344-355.10.1016/S1590-8658(11)60590-2]Search in Google Scholar
[21. Heilmann RM, Cranford SM, Ambrus A, Grützner N, Schellenberg S, Ruaux CG, Suchodolski JS, Steiner JM. Validation of an enzyme-linked immunosorbent assay (ELISA) for the measurement of canine S100A12. Vet Clin Pathol 2016;45:135-47.10.1111/vcp.1232026765807]Search in Google Scholar
[22. Prakash N, Stumbles P, Mansfield C. Initial Validation of Cytokine Measurement by ELISA in Canine Feces. Open Journal of Veterinary Medicine 2013;3:282-288.10.4236/ojvm.2013.36046]Search in Google Scholar
[23. Jovanovic M, Zdravkovic N, Jovanovic I, Radosavljevic G, Gajovic N, Zdravkovic N, Maric V, Arsenijevic N. TGF-β as a marker of ulcerative colitis and disease severity. Ser J Exp Clin Res DOI: 10.1515/sjecr-2017-0019.10.1515/sjecr-2017-0019]Search in Google Scholar
[24. Cui G, Qi H, Gundersen MD, Yang H, Christiansen I, Sørbye SW, Goll R, Florholmen J. Dynamics of the IL-33/ST2 network in the progression of human colorectal adenoma to sporadic colorectal cancer. Cancer Immunol Immunother 2015;64:181-190.10.1007/s00262-014-1624-x25324197]Search in Google Scholar
[25. Mertz KD, Mager LF, Wasmer MH, Thiesler T, Koelzer VH, Ruzzante G, Joller S, Murdoch JR, Brümmendorf T, Genitsch V, Lugli A, Cathomas G, Moch H, Weber A, Zlobec I, Junt T, Krebs P. The IL-33/ST2 pathway contributes to intestinal tumorigenesis in humans and mice. Oncoimmunology 2015;5:e1062966.10.1080/2162402X.2015.1062966476034326942077]Search in Google Scholar
[26. Wagner M, Peterson CG, Ridefelt P, Sangfelt P, Carlson M. Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease. World J Gastroenterol 2008;14:5584-5589.10.3748/wjg.14.5584274634718810778]Search in Google Scholar
[27. Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000;119:15-22.10.1053/gast.2000.852310889150]Search in Google Scholar
[28. Tibble J, Teahon K, Thjodleifsson B, Roseth A, Sigthorsson G, Bridger S, Foster R, Sherwood R, Fagerhol M, Bjarnason I. A simple method for assessing intestinal inflammation in Crohn’s disease. Gut 2000;47:506-513.10.1136/gut.47.4.506172806010986210]Search in Google Scholar
[29. Johne B, Kronborg O, Tøn HI, Kristinsson J, Fuglerud P. A new fecal calprotectin test for colorectal neoplasia. Clinical results and comparison with previous method. Scand J Gastroenterol 2001;36:291-296.10.1080/003655201750074618]Search in Google Scholar
[30. Fang M, Li Y, Huang K, et al. IL33 Promotes Colon Cancer Cell Stemness via JNK Activation and Macrophage Recruitment. Cancer Res 2017;77:2735-2745.10.1158/0008-5472.CAN-16-1602576017028249897]Search in Google Scholar
[31. Li Y, Shi J, Qi S, Zhang J, Peng D, Chen Z, Wang G, Wang Z, Wang L. IL-33 facilitates proliferation of colorectal cancer dependent on COX2/PGE(2). J Exp Clin Cancer Res 2018;37:196.10.1186/s13046-018-0839-7609864030119635]Search in Google Scholar
[32. Zhang Y, Zoltan M, Riquelme E, et al. Immune Cell Production of Interleukin 17 Induces Stem Cell Features of Pancreatic Intraepithelial Neoplasia Cells. Gastroenterology 2018;155:210-223.10.1053/j.gastro.2018.03.041603507529604293]Search in Google Scholar
[33. He Z, Chen L, Souto FO, Canasto-Chibuque C, Bongers G, Deshpande M, Harpaz N, Ko HM, Kelley K, Furtado GC, Lira SA. Epithelial-derived IL-33 promotes intestinal tumorigenesis in Apc (Min/+) mice. Sci Rep 2017;7:5520.10.1038/s41598-017-05716-z551121628710436]Search in Google Scholar
[34. Italiani P, Boraschi D. From Monocytes to M1/M2 Macrophages: Phenotypical vs. Functional Differentiation. Front Immunol 2014;5:514.10.3389/fimmu.2014.00514]Search in Google Scholar
[35. Zhang Y, Davis C, Shah S, Hughes D, Ryan JC, Alto-mare D, Peña MM. IL-33 promotes growth and liver metastasis of colorectal cancer in mice by remodeling the tumor microenvironment and inducing angiogenesis. Mol Carcinog 2017;56:272-287.10.1002/mc.22491563013627120577]Search in Google Scholar
[36. Akimoto M, Maruyama R, Takamaru H, Ochiya T, Takenaga K. Soluble IL-33 receptor sST2 inhibits colorectal cancer malignant growth by modifying the tumour microenvironment. Nat Commun 2016;7:13589.10.1038/ncomms13589512305727882929]Search in Google Scholar
[37. Akbay EA, Koyama S, Liu Y, et al. Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade. J Thorac Oncol 2017;12:1268-1279.10.1016/j.jtho.2017.04.017553206628483607]Search in Google Scholar
[38. Chen Y, Yuan R, Wu X, He X, Zeng Y, Fan X, Wang L, Wang J, Lan P, Wu X. A Novel Immune Marker Model Predicts Oncological Outcomes of Patients with Colorectal Cancer. Ann Surg Oncol 2016;23:826-832.10.1245/s10434-015-4889-126581202]Search in Google Scholar
[39. Liu J, Duan Y, Cheng X, Chen X, Xie W, Long H, Lin Z, Zhu B. IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochem Biophys Res Commun 2011;407:348-354.10.1016/j.bbrc.2011.03.02121396350]Search in Google Scholar
[40. Kyung-Ah Cho, Jee Won Suh, Jung Ho Sohn, Jung Won Park, Hyejin Lee, JiHee Lee Kang, So-Youn Woo, and Young Joo Cho. IL-33 induces Th17-mediated airway inflammation via mast cells in ovalbumin-challenged mice. Am J Physiol Lung Cell Mol Physiol 2012;302:429-440.10.1152/ajplung.00252.201122180658]Search in Google Scholar